The current research was to investigate and develop a transdermal patch of Ivabradine HCl (IBR), a novel heart rate lowering agent. The matrix type transdermal patch was developed by using Durotak 9301 (DT 9301) and polyvinyl pyrrolidone (PVP K30). Four penetration enhancers Isopropyl myristate, transcutol P, oleic acid and limonene were evaluated for their effect on flux of Ivabradine HCl through rat skin. Transcutol containing formulation showed maximum Ivabradine HCl permeation rate followed by drug release from isopropyl myristate, oleic acid and limonene containing formulations. Fourier transform infrared spectroscopy and differential scanning colorimetric study characterize drug compatibility with durotak 9301. There was significant effect of high concentration of propylene glycol and transcutol on adhesion properties of transdermal patches containing durotak and PVP K30. Drug release was facilitated by use of 26.7% w/w PVP K30 and 1% kaoline along with durotak in patch formulation. Selected formulation was screened for skin irritation testing and showed lowest irritation test confirming its applicability for duration of treatment. Pharmacokinetic screening of drug release profile revealed diffusion controlled mechanism (Higuchi’s model). With developed patch formulation, it is possible to deliver Ivabradin HCl at 30.77μg/h.cm2 dosing rate with a transdermal patch lasting for minimum 24 hours.
Loading....